Mark C. Schneyer, the Chief Financial Officer of Acadia Pharmaceuticals, has reported significant stock transactions in a recent SEC filing. The filing, dated October 30, 2026, reveals that Schneyer acquired 6,815 shares of the company's common stock on October 15, 2026, and disposed of 3,321 shares on October 30, 2026, primarily to cover tax obligations related to the vesting of performance stock units.

These transactions are part of Schneyer's ongoing compensation strategy, which includes performance-based stock units granted in May 2023. The recent acquisition reflects a vested interest in the company's performance, while the sale was necessary to meet tax requirements associated with the stock vesting.

Background

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative medicines to address unmet medical needs in the field of central nervous system disorders. The company is classified under the SIC code for Pharmaceutical Preparations [2834]. Acadia is headquartered in San Diego, California, and trades on the NASDAQ under the ticker symbol ACAD. Recent filings include multiple Form 4 submissions, indicating ongoing executive transactions.

What the Filing Says

The SEC filing indicates that Schneyer acquired 6,815 shares on October 15, 2026, and disposed of 3,321 shares on October 30, 2026. The filing notes: "The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of performance stock units." This aligns with compliance requirements under Rule 10b5-1 of the Exchange Act.

Impact

These transactions may affect Acadia's executive compensation structure and shareholder perceptions. Schneyer's actions demonstrate the company's commitment to aligning executive incentives with shareholder interests, particularly in a competitive pharmaceutical market. The ongoing performance-based compensation strategy is a common practice in the industry, aimed at driving long-term growth and accountability.

What's Next

The filing does not say what happens next.